Dataset Information

Global Impact of the COVID-19 Pandemic on Cerebral Venous Thrombosis and Mortality.

ABSTRACT:

Background and purpose

Recent studies suggested an increased incidence of cerebral venous thrombosis (CVT) during the coronavirus disease 2019 (COVID-19) pandemic. We evaluated the volume of CVT hospitalization and in-hospital mortality during the 1st year of the COVID-19 pandemic compared to the preceding year.

Methods

We conducted a cross-sectional retrospective study of 171 stroke centers from 49 countries. We recorded COVID-19 admission volumes, CVT hospitalization, and CVT in-hospital mortality from January 1, 2019, to May 31, 2021. CVT diagnoses were identified by International Classification of Disease-10 (ICD-10) codes or stroke databases. We additionally sought to compare the same metrics in the first 5 months of 2021 compared to the corresponding months in 2019 and 2020 (ClinicalTrials.gov Identifier: NCT04934020).

Results

There were 2,313 CVT admissions across the 1-year pre-pandemic (2019) and pandemic year (2020); no differences in CVT volume or CVT mortality were observed. During the first 5 months of 2021, there was an increase in CVT volumes compared to 2019 (27.5%; 95% confidence interval [CI], 24.2 to 32.0; P<0.0001) and 2020 (41.4%; 95% CI, 37.0 to 46.0; P<0.0001). A COVID-19 diagnosis was present in 7.6% (132/1,738) of CVT hospitalizations. CVT was present in 0.04% (103/292,080) of COVID-19 hospitalizations. During the first pandemic year, CVT mortality was higher in patients who were COVID positive compared to COVID negative patients (8/53 [15.0%] vs. 41/910 [4.5%], P=0.004). There was an increase in CVT mortality during the first 5 months of pandemic years 2020 and 2021 compared to the first 5 months of the pre-pandemic year 2019 (2019 vs. 2020: 2.26% vs. 4.74%, P=0.05; 2019 vs. 2021: 2.26% vs. 4.99%, P=0.03). In the first 5 months of 2021, there were 26 cases of vaccine-induced immune thrombotic thrombocytopenia (VITT), resulting in six deaths.

Conclusions

During the 1st year of the COVID-19 pandemic, CVT hospitalization volume and CVT in-hospital mortality did not change compared to the prior year. COVID-19 diagnosis was associated with higher CVT in-hospital mortality. During the first 5 months of 2021, there was an increase in CVT hospitalization volume and increase in CVT-related mortality, partially attributable to VITT.

SUBMITTER: Nguyen TN

PROVIDER: S-EPMC9194544 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Global Impact of the COVID-19 Pandemic on Cerebral Venous Thrombosis and Mortality.

Nguyen Thanh N TN Qureshi Muhammad M MM Klein Piers P Yamagami Hiroshi H Abdalkader Mohamad M Mikulik Robert R Sathya Anvitha A Mansour Ossama Yassin OY Czlonkowska Anna A Lo Hannah H Field Thalia S TS Charidimou Andreas A Banerjee Soma S Yaghi Shadi S Siegler James E JE Sedova Petra P Kwan Joseph J de Sousa Diana Aguiar DA Demeestere Jelle J Inoa Violiza V Omran Setareh Salehi SS Zhang Liqun L Michel Patrik P Strambo Davide D Marto João Pedro JP Nogueira Raul G RG Kristoffersen Espen Saxhaug ES Tsivgoulis Georgios G Lereis Virginia Pujol VP Ma Alice A Enzinger Christian C Gattringer Thomas T Rahman Aminur A Bonnet Thomas T Ligot Noémie N De Raedt Sylvie S Lemmens Robin R Vanacker Peter P Vandervorst Fenne F Conforto Adriana Bastos AB Hidalgo Raquel C T RCT Mora Cuervo Daissy Liliana DL de Oliveira Neves Luciana L Lameirinhas da Silva Isabelle I Martíns Rodrigo Targa RT Rebello Letícia C LC Santiago Igor Bessa IB Sakelarova Teodora T Kalpachki Rosen R Alexiev Filip F Cora Elena Adela EA Kelly Michael E ME Peeling Lissa L Pikula Aleksandra A Chen Hui-Sheng HS Chen Yimin Y Yang Shuiquan S Roje Bedekovic Marina M Čabal Martin M Tenora Dusan D Fibrich Petr P Dušek Pavel P Hlaváčová Helena H Hrabanovska Emanuela E Jurák Lubomír L Kadlčíková Jana J Karpowicz Igor I Klečka Lukáš L Kovář Martin M Neumann Jiří J Paloušková Hana H Reiser Martin M Rohan Vladimir V Šimůnek Libor L Skoda Ondreij O Škorňa Miroslav M Šrámek Martin M Drenck Nicolas N Sobh Khalid K Lesaine Emilie E Sabben Candice C Reiner Peggy P Rouanet Francois F Strbian Daniel D Boskamp Stefan S Mbroh Joshua J Nagel Simon S Rosenkranz Michael M Poli Sven S Thomalla Götz G Karapanayiotides Theodoros T Koutroulou Ioanna I Kargiotis Odysseas O Palaiodimou Lina L Barrientos Guerra José Dominguo JD Huded Vikram V Nagendra Shashank S Prajapati Chintan C Sylaja P N PN Sani Achmad Firdaus AF Ghoreishi Abdoreza A Farhoudi Mehdi M Sadeghi Hokmabadi Elyar E Hashemilar Mazyar M Sabetay Sergiu Ionut SI Rahal Fadi F Acampa Maurizio M Adami Alessandro A Longoni Marco M Ornello Raffaele R Renieri Leonardo L Romoli Michele M Sacco Simona S Salmaggi Andrea A Sangalli Davide D Zini Andrea A Sakai Kenichiro K Fukuda Hiroki H Fujita Kyohei K Imamura Hirotoshi H Kosuke Miyake M Sakaguchi Manabu M Sonoda Kazutaka K Matsumaru Yuji Y Ohara Nobuyuki N Shindo Seigo S Takenobu Yohei Y Yoshimoto Takeshi T Toyoda Kazunori K Uwatoko Takeshi T Sakai Nobuyuki N Yamamoto Nobuaki N Yamamoto Ryoo R Yazawa Yukako Y Sugiura Yuri Y Baek Jang-Hyun JH Lee Si Baek SB Seo Kwon-Duk KD Sohn Sung-Il SI Lee Jin Soo JS Arsovska Anita Ante AA Chieh Chan Yong CY Wan Zaidi Wan Asyraf WA Wan Yahya Wan Nur Nafisah WNN Gongora-Rivera Fernando F Martinez-Marino Manuel M Infante-Valenzuela Adrian A Dippel Diederik D van Dam-Nolen Dianne H K DHK Wu Teddy Y TY Punter Martin M Adebayo Tajudeen Temitayo TT Bello Abiodun H AH Sunmonu Taofiki Ajao TA Wahab Kolawole Wasiu KW Sundseth Antje A Al Hashmi Amal M AM Ahmad Saima S Rashid Umair U Rodriguez-Kadota Liliana L Vences Miguel Ángel MÁ Yalung Patrick Matic PM Dy Jon Stewart Hao JSH Brola Waldemar W Dębiec Aleksander A Dorobek Malgorzata M Karlinski Michal Adam MA Labuz-Roszak Beata M BM Lasek-Bal Anetta A Sienkiewicz-Jarosz Halina H Staszewski Jacek J Sobolewski Piotr P Wiącek Marcin M Zielinska-Turek Justyna J Araújo André Pinho AP Rocha Mariana M Castro Pedro P Ferreira Patricia P Nunes Ana Paiva AP Fonseca Luísa L Pinho E Melo Teresa T Rodrigues Miguel M Silva M Luis ML Ciopleias Bogdan B Dimitriade Adela A Falup-Pecurariu Cristian C Hamid May Adel MA Venketasubramanian Narayanaswamy N Krastev Georgi G Haring Jozef J Ayo-Martin Oscar O Hernandez-Fernandez Francisco F Blasco Jordi J Rodríguez-Vázquez Alejandro A Cruz-Culebras Antonio A Moniche Francisco F Montaner Joan J Perez-Sanchez Soledad S García Sánchez María Jesús MJ Guillán Rodríguez Marta M Bernava Gianmarco G Bolognese Manuel M Carrera Emmanuel E Churojana Anchalee A Aykac Ozlem O Özdemir Atilla Özcan AÖ Bajrami Arsida A Senadim Songul S Hussain Syed I SI John Seby S Krishnan Kailash K Lenthall Robert R Asif Kaiz S KS Below Kristine K Biller Jose J Chen Michael M Chebl Alex A Colasurdo Marco M Czap Alexandra A de Havenon Adam H AH Dharmadhikari Sushrut S Eskey Clifford J CJ Farooqui Mudassir M Feske Steven K SK Goyal Nitin N Grimmett Kasey B KB Guzik Amy K AK Haussen Diogo C DC Hovingh Majesta M Jillela Dinesh D Kan Peter T PT Khatri Rakesh R Khoury Naim N NN Kiley Nicole L NL Kolikonda Murali K MK Lara Stephanie S Li Grace G Linfante Italo I Loochtan Aaron I AI Lopez Carlos D CD Lycan Sarah S Male Shailesh S SS Nahab Fadi F Maali Laith L Masoud Hesham E HE Min Jiangyong J Orgeta-Gutierrez Santiago S Mohamed Ghada A GA Mohammaden Mahmoud M Nalleballe Krishna K Radaideh Yazan Y Ramakrishnan Pankajavalli P Rayo-Taranto Bliss B Rojas-Soto Diana M DM Ruland Sean S Simpkins Alexis N AN Sheth Sunil A SA Starosciak Amy K AK Tarlov Nicholas E NE Taylor Robert A RA Voetsch Barbara B Zhang Linda L Duong Hai Quang HQ Dao Viet-Phuong VP Le Huynh Vu HV Pham Thong Nhu TN Ton Mai Duy MD Tran Anh Duc AD Zaidat Osama O OO Machi Paolo P Dirren Elisabeth E Rodríguez Fernández Claudio C Escartín López Jorge J Fernández Ferro Jose Carlos JC Mohammadzadeh Niloofar N Suryadevara Neil C NC de la Cruz Fernández Beatriz B Bessa Filipe F Jancar Nina N Brady Megan M Scozzari Dawn D

Journal of stroke 20220531 2

<h4>Background and purpose</h4>Recent studies suggested an increased incidence of cerebral venous thrombosis (CVT) during the coronavirus disease 2019 (COVID-19) pandemic. We evaluated the volume of CVT hospitalization and in-hospital mortality during the 1st year of the COVID-19 pandemic compared to the preceding year.<h4>Methods</h4>We conducted a cross-sectional retrospective study of 171 stroke centers from 49 countries. We recorded COVID-19 admission volumes, CVT hospitalization, and CVT in ...[more]

PMID: 35677980

Similar Datasets

Project description:ObjectiveCerebral venous thrombosis (CVT) caused by vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare adverse effect of adenovirus-based severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) vaccines. In March 2021, after autoimmune pathogenesis of VITT was discovered, treatment recommendations were developed. These comprised immunomodulation, non-heparin anticoagulants, and avoidance of platelet transfusion. The aim of this study was to evaluate adherence to these recommendations and its association with mortality.MethodsWe used data from an international prospective registry of patients with CVT after the adenovirus-based SARS-CoV-2 vaccination. We analyzed possible, probable, or definite VITT-CVT cases included until January 18, 2022. Immunomodulation entailed administration of intravenous immunoglobulins and/or plasmapheresis.ResultsNinety-nine patients with VITT-CVT from 71 hospitals in 17 countries were analyzed. Five of 38 (13%), 11 of 24 (46%), and 28 of 37 (76%) of the patients diagnosed in March, April, and from May onward, respectively, were treated in-line with VITT recommendations (p < 0.001). Overall, treatment according to recommendations had no statistically significant influence on mortality (14/44 [32%] vs 29/55 [52%], adjusted odds ratio [OR] = 0.43, 95% confidence interval [CI] = 0.16-1.19). However, patients who received immunomodulation had lower mortality (19/65 [29%] vs 24/34 [70%], adjusted OR = 0.19, 95% CI = 0.06-0.58). Treatment with non-heparin anticoagulants instead of heparins was not associated with lower mortality (17/51 [33%] vs 13/35 [37%], adjusted OR = 0.70, 95% CI = 0.24-2.04). Mortality was also not significantly influenced by platelet transfusion (17/27 [63%] vs 26/72 [36%], adjusted OR = 2.19, 95% CI = 0.74-6.54).ConclusionsIn patients with VITT-CVT, adherence to VITT treatment recommendations improved over time. Immunomodulation seems crucial for reducing mortality of VITT-CVT. ANN NEUROL 2022;92:562-573.

Dataset Information

Global Impact of the COVID-19 Pandemic on Cerebral Venous Thrombosis and Mortality.

Background and purpose

Methods

Results

Conclusions

Publications

Global Impact of the COVID-19 Pandemic on Cerebral Venous Thrombosis and Mortality.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets